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Available online 3 February 2016Osteoclasts are the only cells in an organism capable of resorbing bone. These cells differentiate frommonocyte/
macrophage lineage cells upon stimulation by receptor activator of NF-κB ligand (RANKL). On the other hand,
osteoclastogenesis is reportedly suppressed by glucose via the downregulation of NF-κB activity through
suppression of reactive oxygen species generation. To examine whether other sugars might also affect osteoclast
development, we compared the effects of monomeric sugars (glucose, galactose,N-acetylglucosamine (GlcNAc),
and N-acetylgalactosamine (GalNAc)) on the osteoclastogenesis of murine RAW264 cells. Our results demon-
strated that, in addition to glucose, both GlcNAc and GalNAc, which each have little effect on the generation of
reactive oxygen species, suppress osteoclastogenesis. We hypothesized that GlcNAcmight affect osteoclastogen-
esis through the upregulation of O-GlcNAcylation and showed that GlcNAc increases global O-GlcNAcylation,
thereby suppressing the RANKL-dependent phosphorylation of NF-κB p65. Furthermore, an inhibitor of N-
acetyl-β-D-glucosaminidase, O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenylcarbamate
(PUGNAc), which also increases O-GlcNAcylation, suppressed the osteoclastogenesis of RAW264 cells and that
of human peripheral blood mononuclear cells. Together, these data suggest that GlcNAc suppresses osteoclast
differentiation in part through the promotion of O-GlcNAcylation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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NF-κB1. Introduction
Bone homeostasis is regulated by the balance between bone
formation and resorption (Yamashita et al., 2012). Only a single bone-
resorbing cell type is found in the body, known as osteoclasts
(Cappariello et al., 2014). Osteoclasts are multinucleated cells that
express tartrate-resistant acid phosphatase (TRAP) and differentiate
from monocyte/macrophage lineage cells upon stimulation with
macrophage colony-stimulating factor (M-CSF) and receptor activator
of nuclear factor-κB (NF-κB) ligand (RANKL). M-CSF promotes the
expression of RANK, the receptor of RANKL. RANKL stimulation
activates downstream signaling molecules including NF-κB and c-Fos,
which induce the expression of NFATc1, a master transcriptional
regulator of osteoclast differentiation. In turn, NFATc1 induces theamine; Glc, glucose; GlcNAc,N-
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. This is an open access article underupregulation of osteoclast-speciﬁc genes including TRAP, cathepsin K,
and matrix metallopeptidase 9 (Asagiri and Takayanagi, 2007; Kuroda
and Matsuo, 2012; Boyce, 2013). Notably, these physiological differ-
entiation processes are well reﬂected in the RANKL-dependent
osteoclastogenic differentiation of RAW264 cells (Hsu et al., 1999).
Osteoclast differentiation is regulated by various molecules, includ-
ing the monomeric sugar glucose (Glc) at high concentration. Glc
suppresses osteoclastogenesis by suppressing the activity of NF-κB
through an anti-oxidative mechanism, which entails suppression of
the RANKL-induced generation of reactive oxygen species (ROS)
(Wittrant et al., 2008), and suppressing the gene expression of several
key differentiation molecules including NFATc1 (Xu et al., 2015). It has
also been reported that a rare monomeric sugar, allose, inhibits
osteoclast differentiation (Yamada et al., 2012). However, the effects
of other common monomeric sugars such as galactose (Gal), N-
acetylglucosamine (GlcNAc), and N-acetylgalactosamine (GalNAc) on
osteoclastogenesis remain undetermined.
Glc is a well-knownmajor energy source. Monomeric sugars includ-
ing Glc are metabolized in cells and become activated as nucleotide
sugars that are used for, e.g., N-glycosylation and O-GlcNAcylation
(Freeze and Elbein, 2009). O-GlcNAcylation is the posttranslational
modiﬁcation of serine or threonine residues in various intracellular
proteins by GlcNAc and is reversibly catalyzed by O-GlcNAc transferase
and β-N-acetylglucosaminidase (O-GlcNAcase) (Butkinaree et al., 1800;the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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with phosphorylation andhas been shown to affect the activities of a va-
riety of signaling molecules including those known to have important
roles in osteoclastogenesis such as p38, ERK, NF-κB, c-Fos, and Akt
(Butkinaree et al., 1800; Hanover et al., 1800).
In the present study, we compared the effects of simple sugars (Glc,
Gal, GlcNAc, and GalNAc) on the RANKL-dependent osteoclastogenic
differentiation of murine RAW264 cells. We also investigated the
role of O-GlcNAcylation in this process by examining the effect of sugars
thereon and the effects of an inhibitor of N-acetyl-β-D-glucosaminidase
(PUGNAc), which increases O-GlcNAcylation, on RAW264 and human
peripheral blood mononuclear cell (PBMC) osteoclast differentiation.
2. Materials and methods
2.1. Cell culture
The mouse macrophage-like RAW264 cell line was obtained from
the RIKEN Cell Bank (Tsukuba, Japan) and maintained in modiﬁed
Eagle's medium alpha (MEMαmedium (Wako, Osaka, Japan) contain-
ing 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) and 1× penicillin/streptomycin (Wako) under a
humidiﬁed atmosphere containing 5% CO2 at 37 °C. Uncharacterized
cryopreserved human PBMCs were obtained from Cellular Technology,
Ltd. (Shaker Heights, OH, USA) and cultured inMEMαmedium contain-
ing 10% heat-inactivated fetal bovine serum and 1× penicillin/
streptomycin.
2.2. Osteoclast differentiation and TRAP staining
RAW264 cells were seeded on a 96-well plate (1000 cells/well) and
cultured for 1 day. Thereafter, the cells were treated with 250 or
500 ng/mL soluble RANKL (sRANKL) (Oriental Yeast, Tokyo, Japan) in
the presence of 20 mM Glc, Gal, GlcNAc, GalNAc, or O-(2-acetamido-2-
deoxy-D-glucopyranosylidene) amino N-phenylcarbamate (PUGNAc;
an inhibitor of N-acetyl-β-D-glucosaminidase) (all from Wako) and
allowed to differentiate for 4 days. The sugars were dissolved in
phosphate-buffered saline (PBS); PUGNAc was dissolved in DMSO.
Human PBMCs were seeded on a 96-well plate (1 × 105 cells/well)
and cultured for 1 day. Then the cells were treated with 50 ng/mL
sRANKL and 25 ng/mL human M-CSF (PeproTech, Rocky Hill, NJ, USA)
in the presence of 20 mM GlcNAc or 10 μM PUGNAc and allowed to
differentiate for 8 days. Media were replenished every 2 days.
Differentiated cells were washed with PBS and then treated with 4%
paraformaldehyde solution for 10min at room temperature. After being
washed againwith PBS, the cellswere treatedwith PBS and then stained
with a TRAP staining solution containing 50 mM sodium tartrate,
45 mM sodium acetate, pH 5.2, 0.1 mg/mL naphthol AS-MX phosphate
(Sigma-Aldrich, St. Louis, MO, USA), and 0.6 mg/mL fast red violet LB
(Sigma-Aldrich), pH 5.2, for 1 h or longer at room temperature. The
cells were viewed under a TC5400 microscope (Meiji Techno, Saitama,
Japan) equipped with a Moticom 2000 digital camera (Shimadzu,
Kyoto, Japan), and TRAP-positive cells that stained red and contained
three or more nuclei were counted. Photographs were taken with a
10× objective.
2.3. TRAP enzyme activity assay
RAW264 cells were allowed to differentiate as described in
Section 2.2. After 4 days, the cells were washed with PBS and lysed
with 100 μL TRAP buffer (50 mM sodium tartrate, 50 mM sodium
acetate, 150 mM KCl, 0.1% TritonX-100, 1 mM sodium ascorbate,
and 0.1 mM FeCl3, pH 5.2) for 10 min at 4 °C. The prepared cell
extract (10 μL) was then added to 100 μL TRAP buffer containing
2.5 mM p-nitrophenyl phosphate (Thermo Fisher Scientiﬁc) as a TRAP
substrate, and the reaction mixture was incubated for 1 h at 37 °C.After the addition of 50 μL 0.9 M NaOH to the mixture to stop the reac-
tion, the absorbance at 405 nm was measured using a SpectraMax M5
microplate reader (Molecular Devices, Sunnyvale, CA, USA).
2.4. Real-time PCR
RAW264 cells were allowed to differentiate for 4 days as described
in Section 2.2. Total RNAextraction and cDNA synthesiswere performed
using the Power SYBR® Green Cells-to-CT™ Kit (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer's instruction. In
brief, cells differentiated in a 96-well plate were washed with PBS and
lysedwith 50 μL lysis solution containingDNase I. A portion of the lysate
(10 μL) was used for reverse transcription with both random primers
and oligo dT. Real-time PCR was performed with the StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and
the Power SYBR® Green PCR Master Mix (Life Technologies). All PCR
products were ampliﬁed with 40 cycles of denaturation (95 °C, 15 s)
and annealing and extension (65 °C, 15 s). Hypoxanthine guanine
phosphoribosyl transferase (Hprt) was used as an internal control, and
data were analyzed using the 2−ΔΔCt method. The primers used for
PCR were as follows: Hprt, 5′-GCT CGA GAT GTC ATG AAG GAG-3′ and
5′-CAG CAG GTC AGC AAA GAA CTT-3′; cathepsin K, 5′-GGC TGT GGA
GGC GGC TAT-3′ and 5′-AGA GTC AAT GCC TCC GTT CTG-3′; andmatrix
metallopeptidase 9, 5′-AAA GAC CTG AAA ACC TCC AAC CT-3′ and 5′-
GCC CGG GTG TAA CCA TAG C-3′. The primers for Hprt were designed
according to themethod described by Nairn et al. (2008), and the others
were according to that by Kim et al. (2014)).
2.5. Staining and measurement of ROS
For ROS staining, RAW264 cells were seeded on a 12-well plate
(6000 cells/well) and cultured for 1 day. Then the cells were treated
with 500 ng/mL sRANKL in the presence of 20 mM sugars and allowed
to differentiate for 4 days. Differentiated cells were washed twice with
PBS and then stained with PBS containing 5 μM ﬂuorescent ROS detec-
tion reagent (5-(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein
diacetate, acetyl ester (CM-H2DCFDA); Life Technologies) for 30 min at
room temperature. Thereafter, the cells were washed twice with PBS,
and the resultant green ﬂuorescence was viewed using a FLoid™ Cell
Imaging Station (Life Technologies) with a 20× objective.
For ROS measurement, RAW264 cells were seeded on a 96-well
white plate (1000 cells/well) and cultured for 1 day. Then the cells
were treated with 500 ng/mL sRANKL in the presence of 20 mM sugars
and allowed to differentiate for 4 days. Differentiated cells were stained
with PBS containing 10 μM CM-H2DCFDA for 1 h at room temperature.
The cells were washed twice with PBS, and the ﬂuorescent dye was
extracted by incubation with 100 μL PBS containing 0.2% TritonX-100
for 30 min at 4 °C. Thereafter, the ﬂuorescence (excitation 485 nm,
emission 538 nm) was measured using a SpectraMax M5 microplate
reader.
2.6. Western blotting
For immunoblotting analysis, cellswerewashedwith PBS and lysed in
200 μL sample buffer (50mMTris–HCl, pH 6.8, 1% sodiumdodecyl sulfate,
10% glycerol, 0.01% bromophenol blue, and 2% 2-mercaptoethanol) with
sonication. After boiling and centrifugation, the resulting supernatants
were subjected to sodiumdodecyl sulfate-polyacrylamide gel electropho-
resis, and the separated proteins were transferred onto nitrocellulose
membranes (Bio-Rad Laboratories, Berkeley, CA, USA) using a wet
electroblotting system for the detection of O-GlcNAcylated proteins or
using the iBlot Gel Transfer Device (Life Technologies) for the other pro-
teins of interest. Immunoblotting was performed on an iBind™Western
Device (Life Technologies) according to the manufacturer's instructions
using horseradish peroxidase-conjugated anti-O-GlcNAc (CTD110.6)
mouse monoclonal antibody, anti-IκBα mouse monoclonal antibody,
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NF-κB p65 rabbit monoclonal antibody (Cell Signaling Technology, Dan-
vers, MA, USA). These antibodies were diluted ~1:1000 with 1× iBind™
solutionprior to use. Theblotswere visualizedwith a LuminataCrescendo
(Merck Millipore), and signals were detected using a ChemiDoc XRS+
(Bio-Rad). Equal protein loading was conﬁrmed by Coomassie brilliant
blue staining.
2.7. Resorption assay
To measure resorption, RAW264 cells with less than three passages
were seeded on an Osteoassay surface stripwell microplate (Corning,
Cambridge, MA, USA) at a density of 2000 cells/well and cultured for
1 day. Then the cells were treated with 500 ng/mL sRANKL in the pres-
ence of 20mMGlcNAc or 10 μMPUGNAc.Mediawere replenished every
3 days. After 14 days, the plate was incubated with 10% bleach to stripFig. 1. GlcNAc and GalNAc suppress the osteoclastic differentiation of RAW264 cells. RAW264
TRAP staining (A), and TRAP-positive multinuclear cells were counted (B) or were subjected
marker genes cathepsin K (D) and matrix metallopeptidase 9 (E) using cDNA prepared fro
control (PBS with RANKL).the cells, rinsedwith distilledwater, air dried, and imagedusing a digital
camera. The percentage of resorbed surface area was analyzed using
NIH ImageJ software (Schneider et al., 2012).
Human PBMCs were seeded at a density of 1 × 105 cells/well and
cultured for 1 day. Then the cells were treated with 50 ng/mL sRANKL
and 25 ng/mL M-CSF in the presence of 20 mM GlcNAc or 10 μM
PUGNAc. Media were replenished every 2 days. After 14 days, the
resorbed area was analyzed as described above.2.8. Statistics
Data are presented asmeans±S.D. Comparisons between twogroups
were analyzed using Student's two-tailed t-tests. p-values b 0.05 were
considered statistically signiﬁcant. Each experiment was repeated at
least two times with similar results.cells were treated with RANKL and various sugars. RANKL-treated cells were subjected to
to TRAP enzyme activity assay (C). (D and E) Real-time PCR analysis of the osteoclast
m RANKL-treated RAW264 cells. Data are expressed as the means ± S.D. *p b 0.05 vs.
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3.1. Glc, GlcNAc, and GalNAc suppress the osteoclastic differentiation of
RAW264 cells
To clarify the effect of simple sugars on the formation of osteoclasts,
we stimulated RAW264 cells with RANKL in the presence of various
sugars at 20mM.We used equal high concentrations (20mM) of sugars
for osmotic control although the concentration of the sugars other than
Glc is much higher than their physiological or pathological concentra-
tions. After 4 days, TRAP-positive cells were stained (Fig. 1A), and
TRAP-positive multinuclear cells were counted (Fig. 1B). Glc showed a
suppressive effect on the formation of osteoclasts, as had been reported
by Wittrant et al. (2008)), as did GlcNAc and GalNAc. In contrast, Gal
showed little effect on osteoclast formation. To conﬁrm these results,
we performed a TRAP enzyme activity assay and found that Glc, GlcNAc,
and GalNAc also suppressed RANKL-dependent upregulation of TRAP
enzyme activity (Fig. 1C) without affecting cell viability (data not
shown). We also examined the effect of 20 mMmannose on osteoclas-
togenesis; however, mannose showed cytotoxicity at this concentration
(data not shown). Therefore, we excluded mannose from the subse-
quent experiments.
Next, to examine the effect of sugars on osteoclastogenesis at the
molecular level, the expression of osteoclastmarker geneswas analyzed
by real-time PCR. RAW264 cells were stimulated with RANKL in the
presence of various sugars, and the mRNA expression of cathepsin K
and matrix metallopeptidase 9 was analyzed after 4 days (Fig. 1D and
E). RANKL stimulation induced the expression of these genes, whereas
Glc, GlcNAc, and GalNAc suppressed their RANKL-dependent upregula-
tion. Although the effects of GalNAc were relatively weak and its effect
on cathepsin K gene expression was not statistically signiﬁcant, GalNAc
tended to suppress the expression of these genes. On the other hand,
consistent with the results of TRAP-staining and the enzyme assay, Gal
showed little effect on the expression of osteoclast marker genes.Fig. 2.Among the testedmonomeric sugars, only Glc suppressed the RANKL-dependent upregu
was detected using CM-H2DCFDA (A), and the resultant ﬂuorescence intensity was measured3.2. GlcNAc and GalNAc suppress osteoclastic differentiation by different
mechanisms than that used by Glc
As our results indicated that not only Glc but alsoGlcNAc andGalNAc
could suppress the RANKL-dependent osteoclastogenesis of RAW264
cells, we next investigated the underlying molecular mechanisms.
Wittrant et al. reported that high concentrations of Glc inhibited osteo-
clast formation, ROS production, and caspase-3 and NF-κB activity and
suggested that the inhibition of redox-sensitive NF-κB activity through
an anti-oxidative mechanismwas important for the inhibition of osteo-
clast formation by Glc (Wittrant et al., 2008). Therefore, we compared
the effects of sugars on ROS production.
RAW264 cells were treated with RANKL in the presence of various
sugars at 20 mM and then stained with the ﬂuorescent ROS detection
reagent CM-H2DCFDA followed by observation under a ﬂuorescence
microscope and quantiﬁcation of ﬂuorescent intensity (Fig. 2). From
this, we determined that RANKL induced ROS generation whereas Glc
suppressed its induction. In contrast, Gal, GlcNAc, and GalNAc showed
little effect on RANKL-induced ROS generation. These results indicated
that GlcNAc and GalNAc could suppress osteoclast formation through
different mechanisms from that used by Glc, i.e., without inhibiting
ROS generation.
3.3. Upregulation of O-GlcNAcylation suppresses osteoclastogenic
differentiation partly through the inhibition of NF-κB p65 phosphorylation
Although both GlcNAc and GalNAc have suppressive effects on the
osteoclastogenesis of RAW264 cells, the effect of GlcNAc is somewhat
more substantial than that of GalNAc. Therefore, we focused on GlcNAc
in the following experiments.
GlcNAc is metabolized intracellularly to UDP-GlcNAc, which is used
for, e.g., O-GlcNAcylation and N-glycosylation (Freeze and Elbein,
2009).O-GlcNAcylationmodiﬁes numerous nucleocytoplasmic proteins
and plays important roles in the regulation of various signalinglation of ROS. RAW264 cells were treatedwith RANKL and various sugars. Intracellular ROS
(B). Data are expressed as the means ± S.D. *p b 0.05 vs. control (PBS with RANKL).
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whose activation was shown to be important for osteoclastogenesis
(Boyce, 2013), was found to be suppressed by the upregulation of
O-GlcNAcylation (Xing et al., 2011; Zou et al., 2009). Therefore we
investigated whether GlcNAc upregulates O-GlcNAcylation and
whether such upregulation might affect osteoclastogenesis.
To clarify the effects of sugars on O-GlcNAcylation, RAW264 cells
were treated with RANKL in the presence of various sugars at 20 mM
and subjected to western blotting, and the O-GlcNAcylated proteins
were then detected using an anti-O-GlcNAc antibody (Fig. 3A). We
found that RANKL-stimulation in the presence of either GlcNAc or
GalNAc resulted in a global increase of O-GlcNAcylation. This result
suggested that the upregulation of O-GlcNAcylation suppressed osteo-
clast formation. Therefore, we next investigated the effect of increasedFig. 3.Upregulation ofO-GlcNAcylation byGlcNAc and PUGNAc suppresses osteoclastic differen
ed with sRANKL in the presence of various sugars. Following 4 day differentiation, the cell lysa
totalO-GlcNAcylated proteinsweremeasured using ImageJ software. (B) RAW264 cells were tre
and subjected to western blotting with an anti-O-GlcNAc antibody. (C) RAW264 cells were tr
RANKL-treated cells were subjected to TRAP staining. (D) RAW264 cells were seeded on oste
10 μM PUGNAc. After 14 days, the resorption areas on the osteoclast assay surface plates we
stimulated with sRNAKL, harvested at the indicated time, and subjected to western blotting. DO-GlcNAcylation on osteoclastogenesis. We found that the global O-
GlcNAcylation of RAW264 cells increased when the cells were treated
with GlcNAc or PUGNAc, an inhibitor of N-acetyl-β-D-glucosaminidase,
which functions as an O-GlcNAcase (Fig. 3B). Furthermore, we investi-
gated the effect of GlcNAc or PUGNAc on the formation of osteoclasts
(Fig. 3C) and on the bone resorption activity of differentiated osteoclasts
(Fig. 3D). We found that both compounds suppressed the number of
formed osteoclasts and tended to suppress bone resorption activity,
although the suppressive effect of PUGNAc was weaker than that of
GlcNAc. These results indicate that the increase of O-GlcNAcylation
suppressed the RANKL-dependent formation of osteoclasts from
RAW264 cells.
The NF-κB signaling pathway is important for RANKL-dependent
osteoclastogenesis. This pathway is reportedly suppressed by a globaltiation partly via suppression of NF-κB p65 phosphorylation. (A) RAW264 cells were treat-
tes were subjected to western blotting with an anti-O-GlcNAc antibody. The intensities of
atedwith the indicated concentrations of GlcNAc or PUGNAc, an inhibitor of O-GlcNAcase,
eated with RANKL in the presence of the indicated concentrations of GlcNAc or PUGNAc.
oclast assay surface plates and treated with RANKL in the presence of 20 mM GlcNAc or
re analyzed. (E) RAW264 cells were pretreated with PUGNAc or DMSO for 4 h and then
ata are expressed as the means ± S.D. *p b 0.05 vs. control (PBS or DMSO with RANKL).
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phosphorylation without an associated effect on IκB degradation (Xing
et al., 2011). Therefore, we hypothesized that the suppression of NF-
κB signaling by the increase of O-GlcNAcylation was one of the
mechanisms underlying the suppressive effect of GlcNAc and PUGNAc
on osteoclastogenesis. To test this hypothesis, RAW264 cells were
pretreated with PUGNAc for 4 h and then stimulated with RANKL,
followed by western blotting with anti-IκB, anti-phospho-p65, and
anti-p65 antibodies (Fig. 3E).We found that RANKL stimulation induced
the degradation of IκB and the phosphorylation of p65. However,
pretreatment with PUGNAc suppressed the RANKL-dependent induc-
tion of p65 phosphorylation with little effect on IκB degradation.
Pretreatment with GlcNAc showed similar results (data not shown),
although the effect was less clear than that generated by PUGNAc, pre-
sumably because the increase in O-GlcNAcylation mediated by GlcNAc
under this condition was smaller than that by PUGNAc (data not
shown). Therefore, we concluded that O-GlcNAcylation upregulation
could suppress the osteoclastogenic differentiation of RAW264 cells
partly through the inhibition of NF-κB p65 phosphorylation, although
other signaling pathways might also be affected by O-GlcNAcylation
and have a role in the formation of osteoclasts.
3.4. Upregulation of O-GlcNAcylation suppresses the osteoclastogenesis of
human PBMCs
To determine the effect of increased O-GlcNAcylation under a more
physiological condition, we treated human PBMCs with RANKL and
M-CSF in the presence of GlcNAc or PUGNAc. The number of formed os-
teoclasts was examined by TRAP staining (Fig. 4A), and the activity of
the osteoclasts was examined using a bone resorption assay (Fig. 4B).
We found that both GlcNAc and PUGNAc suppressed osteoclast forma-
tion and activity. These results are consistent with the results obtained
using RAW264 cells; therefore, we concluded that the upregulation of
O-GlcNAcylation generally suppressed osteoclast differentiation. How-
ever, the effect of PUGNAc on PBMCs was more signiﬁcant than that
on RAW264 cells, and this differencemight suggest that PUGNAc affects
the early phase of differentiation, e.g., M-CSF-induced RANK expression.
4. Discussion
In the present study, using RAW264 cells as a model system, we
compared the effects of simple sugars on osteoclastogenesis, although
the concentration (20 mM) of the sugars other than Glc is much higherFig. 4.GlcNAc and PUGNAc suppress the osteoclastic differentiation of human PBMCs. (A) Hum
allowed to differentiate for 8 days. TRAP-positivemultinuclear cellswere counted. (B) HumanP
in the presence of GlcNAc or PUGNAc. After 14 days, the resorption areas on the osteoclast assay
(PBS or DMSO).than their physiological or pathological concentrations. We found that
GlcNAc and GalNAc suppressed osteoclastogenesis without affecting
ROS generation, whereas the standard monomeric sugar Glc affected
ROS generation as reported previously (Wittrant et al., 2008). These
ﬁndings indicated different underlying molecular mechanisms for the
suppression of osteoclastogenesis among these sugars. PUGNAc, an
inhibitor of O-GlcNAcase, and GlcNAc both suppressed the osteoclasto-
genesis of RAW264 cells and human PBMCs. Supplemental GlcNAc is
thought to couple with uridine diphosphate (UDP) to form UDP-
GlcNAc, an activated form of GlcNAc that is utilized as a donor substrate
for O-GlcNAcylation. Since supplemental GalNAc also somewhat
increased O-GlcNAcylation in these cells, consistent with a report
that UDP-GlcNAc is exchangeable with UDP-GalNAc (Freeze and
Elbein, 2009), the suppressive effect of GalNAc on osteoclastogenesis
might be due in part to the upregulation of O-GlcNAcylation.
Furthermore, we showed that the upregulation of O-GlcNAcylation
suppresses the RANKL-dependent phosphorylation of NF-κB p65.
Since O-GlcNAcylation might modify the functions of various proteins
(Butkinaree et al., 1800; Hanover et al., 1800), O-GlcNAcylation might
therefore affect osteoclastogenesis not only via p65 phosphorylation
but also through other mechanisms.
Recently, it was reported that a global increase of O-GlcNAcylation
promoted the osteoblastic differentiation of MC3T3-E1 cells but had lit-
tle effect on the osteoclast differentiation of RAW264 cells (Koyama and
Kamemura, 2015). This seems inconsistent with our results; however,
this discrepancy might be due to differences in the conditions used to
induce differentiation such as cell density, RANKL concentration, and
assay conditions. Furthermore, to assess differentiation, Koyama and
Kamemura performed qRT-PCR of the TRAP gene and quantiﬁcation of
TRAP activity (Koyama and Kamemura, 2015), whereas we counted
the number of formed osteoclasts and measured the bone resorption
area. Since our assay assesses a later phase of differentiation, we might
have been able to detect the suppressive effect of O-GlcNAcylation on
osteoclast differentiation. In either case, it seems feasible that the upreg-
ulation of global O-GlcNAcylation that increases bone formation by
promoting osteoblast differentiation would also decrease bone resorp-
tion by suppressing osteoclast differentiation. Therefore, the regulation
of O-GlcNAcylation might serve as a target for treating bone diseases
such as osteoporosis, and molecules such as GlcNAc or its derivatives
that upregulate O-GlcNAcylation might become useful therapeutic
agents.
The suppressive effect of GlcNAc on osteoclastogenesis was stronger
than that of PUGNAc (Fig. 4C and D), although O-GlcNAcylation wasan PBMCswere treatedwith sRANKL andM-CSF in the presence of GlcNAc or PUGNAc and
BMCs seeded on osteoclast assay surfacemicroplateswere treatedwith sRANKL andM-CSF
surface plates were analyzed. Data are expressed as themeans± S.D. *p b 0.05 vs. control
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(Fig. 4B). These results suggest that GlcNAc affects osteoclastogenesis
not only through O-GlcNAcylation but also through other mechanisms.
The activated UDP-GlcNAc resulting from cell metabolism of GlcNAc is
used not only for O-GlcNAcylation but also for other types of glycosyla-
tion such as N-glycosylation. It has been reported that GlcNAc increases
the branching of N-glycans and that this increase resulted in an in-
creased afﬁnity of N-glycan for galectins, a family of galactose-speciﬁc
lectins (Lau et al., 2007; Johswich et al., 2014; Boscher et al., 2011).
Since galectin-3 and -9 have suppressive activity on osteoclastogenesis
(Li et al., 2009; Moriyama et al., 2014), GlcNAc might suppress osteo-
clastogenesis through an increase of N-glycan branching and the
suppressive activity of galectins. In addition, given that N-glycan can
be capped with sialic acid, and sialic acid and siglec-15, a sialic acid
binding lectin, have been reported to have roles in osteoclastogenesis
(Takahata et al., 2007; Hiruma et al., 2011; Ishida-Kitagawa et al.,
2012; Kameda et al., 2013), GlcNAc might affect osteoclastogenesis by
modulating the interaction between sialic acid and its binding
partner(s). On the other hand, UDP-GlcNAc and UDP-GalNAc might
be used for the biosynthesis of glycosaminoglycans. Since glycosamino-
glycans also affect osteoclast differentiation (Ariyoshi et al., 2005;
Shinmyouzu et al., 2007; Ariyoshi et al., 2008; Ling et al., 2010;
Salbach et al., 2012), it is further possible that GlcNAc affects osteoclas-
togenesis through the modulation of glycosaminoglycan biosynthesis.
In conclusion, the results of the present study demonstrated that
sugars in addition to Glc can affect osteoclast development and that
GlcNAc suppresses osteoclastogenesis in part via the upregulation of
O-GlcNAcylation, although other mechanisms might also be involved,
as described above. Further studies into these processes might reveal a
new mechanism for the regulation of osteoclast differentiation by
sugar molecules. In turn, this might provide new strategies for the
development of clinical treatments or preventative measures for bone
diseases.
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